首页 / 产品 / 抗体 / 一抗

Mouse Monoclonal CD79A Antibody

  • 中文名: CD79A抗体
  • 别    名: IGA; MB-1
货号: IPD32086
Price: ¥1280
数量:
大包装询价

验证与应用

应用及物种
WB 咨询技术 Human,Mouse,Rat
IF 咨询技术 Human,Mouse,Rat
IHC 咨询技术 Human,Mouse,Rat
ICC 1/200 - 1/1000 Human,Mouse,Rat
FCM 1/200 - 1/400 Human,Mouse,Rat
Elisa 1/10000 Human,Mouse,Rat

产品详情

参考文献

以下是关于CD79A抗体的3篇代表性文献,按文献名称、作者和摘要内容简要概括:

---

1. **文献名称**:*CD79a: A Review of Its Role in B-Cell Development and Malignancies*

**作者**:van der Burg, M., et al.

**摘要**:该综述总结了CD79a作为B细胞受体(BCR)信号复合物的关键成分,在B细胞发育和功能中的作用。文章重点讨论了CD79a抗体在诊断B细胞恶性肿瘤(如弥漫大B细胞淋巴瘤)中的应用,并分析了其作为免疫组化标记物的敏感性和特异性。

2. **文献名称**:*Targeting CD79A in B-Cell Receptor Signaling: Insights from Monoclonal Antibody Development*

**作者**:Dörner, T., et al.

**摘要**:研究报道了一种新型抗CD79A单克隆抗体的开发,用于抑制过度激活的BCR信号通路。实验表明,该抗体能有效阻断B细胞异常活化,为自身免疫疾病(如系统性红斑狼疮)的靶向治疗提供了潜在策略。

3. **文献名称**:*CD79A Mutations and Altered B-Cell Signaling in Chronic Lymphocytic Leukemia*

**作者**:Davis, R.E., et al.

**摘要**:通过CD79A抗体检测慢性淋巴细胞白血病(CLL)患者的样本,研究发现CD79A的突变导致BCR信号传导异常,揭示了其在疾病进展中的作用,并提出针对该通路的治疗可能改善患者预后。

---

如需更详细文献信息(期刊、年份等),可进一步补充关键词或限定条件。

背景信息

CD79a, a key component of the B-cell receptor (BCR) complex, is encoded by the CD79A gene and pairs with CD79b to form a heterodimer essential for BCR surface expression and signal transduction. As a transmembrane immunoglobulin, CD79a contains an immunoreceptor tyrosine-based activation motif (ITAM) that recruits kinases like Syk upon antigen binding, initiating downstream signaling critical for B-cell development, activation, and differentiation.

CD79a antibodies are valuable tools in research and diagnostics, specifically targeting the invariant CD79a protein expressed exclusively on B-cells. These antibodies enable the identification of B-cell lineages in tissues and blood, aiding in the classification of B-cell malignancies such as chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), and multiple myeloma. Unlike markers like CD20 or CD19. CD79a retains expression in certain immature B-cell neoplasms and plasma cells, enhancing diagnostic accuracy.

Therapeutically, CD79a has emerged as a potential target for antibody-drug conjugates (ADCs) or bispecific antibodies designed to direct immune cells against malignant B-cells. Recent studies also explore its role in autoimmune diseases, where aberrant BCR signaling contributes to pathology. However, targeting CD79a presents challenges due to its broad expression on healthy B-cells, necessitating precise engineering to balance efficacy and toxicity. Ongoing research continues to refine CD79a antibody applications, bridging gaps in understanding B-cell biology and improving clinical outcomes.

客户数据及评论

折叠内容

大包装询价

×